Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + R-CHOEP in young high-risk DLBCL
NCT03399513Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- May 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Universitätsklinikum Münster. Started May 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03399513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399513.